DCGI sends show cause notice to Serum Institute of India for not pausing trial of Covishield
Shortpedia
Content Team
Image Credit: shortpedia
The Drugs Regulator General of India (DCGI) has issued a show-cause notice to pharma giant Serum Institute of India (SII) asking for an explanation as to why the ongoing clinical trial of Covishield vaccine candidate has not been suspended till doubts about patient safety are cleared. The drug regulator's move comes after AstraZeneca, paused its trial as a volunteer developed an unexplained illness.
